Both studies had demonstrated that some people with CF, who do not tolerate the full dose of ETI as a result of psychiatric adverse events, may require individualised dose adjustments to minimise adverse events to enable them to continue CFTR modulator therapy [31,32]. This evidence concerns the gene CFTR and cystic fibrosis.